|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
89.31 Million
|
|
CAGR (2025-2030)
|
10.77%
|
|
Fastest Growing Segment
|
Instruments
|
|
Largest Market
|
North India
|
|
Market Size (2030)
|
USD 165.35 Million
|
Market Overview
India Minimally Invasive Biopsy
Techniques Market was valued at USD 89.31 Million in 2024 and is expected to
reach USD 165.35 Million by 2030 with a CAGR of 10.77% during the forecast
period. The India Minimally Invasive Biopsy Techniques Market is experiencing
robust growth, driven by the rising prevalence of cancer, increasing demand for
early disease detection, and advancements in biopsy technologies. The expanding
healthcare infrastructure, particularly in urban regions like Delhi, Mumbai,
Bengaluru, and Chennai, has facilitated the adoption of innovative biopsy
techniques, reduced patient discomfort and improving diagnostic accuracy.
Government initiatives promoting cancer screening programs and
increased healthcare spending are fueling market expansion.
However, challenges such as the high
cost of advanced biopsy instruments, limited accessibility in rural areas, and
a shortage of skilled professionals continue to hinder widespread adoption. The
market also faces regulatory hurdles, with stringent approval processes for new
biopsy devices potentially delaying product launches. Despite these challenges,
the rising awareness about minimally invasive procedures and the growing
preference for liquid biopsies over traditional methods are expected to drive market
growth, making India a key market for biopsy device manufacturers in the coming
years.
Key Market Drivers
Rising
Cancer Prevalence
The rising prevalence of cancer in India
is a significant driver propelling the Minimally Invasive Biopsy Techniques
Market, as early and accurate diagnosis remains critical in improving treatment
outcomes. One in nine Indians is likely to develop cancer in their lifetime,
making the disease a growing public health concern. Among the various cancer
types, lung cancer is the leading malignancy among males, whereas breast cancer
dominates among females, reflecting the urgent need for enhanced diagnostic capabilities.
The overall incidence of cancer cases in India is expected to rise by 12.8%
by 2025 compared to 2020, underscoring the increasing burden on healthcare
infrastructure.
The surge in cancer cases can be
attributed to multiple factors, including lifestyle changes, rising pollution
levels, increasing tobacco consumption, and genetic predisposition.
Urbanization and industrialization have led to greater exposure to
environmental carcinogens, while shifting dietary habits and sedentary
lifestyles have contributed to a higher risk of obesity-related cancers. India’s aging population is more vulnerable to malignancies,
further escalating demand for precise and less invasive diagnostic procedures. In
2023, approximately a third of the total population in India lived in cities.
The trend shows an increase of urbanization by more than 4 percent in the last
decade, meaning people have moved away from rural areas to find work and make a
living in the cities.
Also, Industrial Production in India
increased 3.20 percent in December of 2024 over the same month in the previous
year. Industrial Production in India averaged 5.98% from 1994 until 2024,
reaching an all-time high of 133.50 percent in April of 2021 and a record low
of -57.30% in April of 2020.
Despite the growing burden, cancer
detection in India often occurs at advanced stages due to low awareness, lack
of screening programs in rural areas, and limited access to healthcare
facilities. This late diagnosis reduces survival rates and increases treatment
complexity. Minimally invasive biopsy techniques, such as liquid biopsies,
fine-needle aspiration biopsies (FNAB), and core needle biopsies, are gaining
traction as they enable early-stage cancer detection with reduced patient
discomfort, quicker recovery, and lower risk of complications. These techniques
are particularly beneficial for individuals who cannot undergo traditional
surgical biopsies due to health constraints.
Expanding
Healthcare Infrastructure
India’s expanding healthcare
infrastructure is a key driver accelerating the growth of
the Minimally Invasive Biopsy Techniques Market, as improved medical
facilities and accessibility enhance the adoption of advanced diagnostic
technologies. The country has made significant strides in strengthening its
healthcare system, with a vast network of medical facilities catering to both
urban and rural populations. As of March 31, 2023, India had 1,69,615
Sub-Centres (SCs), 31,882 Primary Health Centres (PHCs), 6,359 Community Health
Centres (CHCs), 1,340 Sub-Divisional/District Hospitals (SDHs), 714 District
Hospitals (DHs), and 362 Medical Colleges (MCs), reflecting the
government’s commitment to expanding healthcare services across all regions.
The rapid growth of multi-specialty hospitals,
diagnostic centers, and private healthcare institutions has significantly
improved access to minimally invasive biopsy techniques, particularly in
metro cities such as Delhi, Mumbai, Bengaluru, and Chennai. Private sector
investments and public-private partnerships (PPPs) have led to the
establishment of state-of-the-art oncology centers, enabling the
widespread adoption of biopsy innovations like liquid biopsies,
fine-needle aspiration biopsies (FNAB), and image-guided core biopsies. These
advancements help detect cancers at an earlier stage, improving treatment
outcomes and reducing the need for invasive surgical procedures.
Despite these developments, rural and
tier-2/tier-3 cities still face gaps in access to advanced diagnostic
solutions, primarily due to limited infrastructure, a shortage of skilled
medical professionals, and the high cost of specialized medical equipment.
However, government initiatives such as Ayushman Bharat, the National
Health Mission (NHM), and the Pradhan Mantri Jan Arogya Yojana
(PM-JAY) are working to bridge this divide by strengthening the primary
and secondary healthcare ecosystem. The growing establishment
of telemedicine services and mobile diagnostic units is also
improving early cancer detection in remote areas, thereby increasing the demand
for minimally invasive biopsy techniques.
Download Free Sample Report
Key Market Challenges
High
Cost of Advanced Biopsy Techniques
One of the significant challenges in the India
Minimally Invasive Biopsy Techniques Market is the high cost
associated with advanced biopsy procedures and equipment, which limits
accessibility, particularly in lower-income and rural areas. While minimally
invasive biopsy techniques such as liquid biopsy, fine-needle aspiration
biopsy (FNAB), and image-guided biopsies offer numerous advantages,
including reduced patient discomfort, quicker recovery times, and higher
diagnostic accuracy, their high price points remain a barrier to widespread
adoption.
The cost of liquid biopsy tests—which are gaining
traction due to their ability to detect cancer using a simple blood sample—can
range from INR 10,000 to INR 50,000 per test, making them unaffordable for
a large segment of the population. Similarly, core needle biopsies and
stereotactic biopsies require sophisticated imaging technologies such
as MRI, CT scans, and ultrasound guidance, significantly increasing
operational costs for healthcare providers. Many hospitals and diagnostic
centers, especially in tier-2 and tier-3 cities, struggle to invest in
these high-end diagnostic solutions due to financial constraints.
Moreover, the import dependency on biopsy
instruments and reagents further escalates costs. India relies heavily on
global manufacturers for advanced biopsy equipment, and fluctuations in foreign
exchange rates, import duties, and supply chain disruptions contribute to price
volatility. Unlike traditional biopsy methods, robotic-assisted biopsy
systems and AI-driven pathology solutions, which offer higher precision,
require substantial capital investment, restricting their availability to only
a few premium healthcare institutions.
Key Market Trends
Growing
Preference for Minimally Invasive Procedures
A significant trend shaping the India Minimally
Invasive Biopsy Techniques Market is the growing preference for
minimally invasive procedures, driven by increasing patient awareness,
advancements in technology, and the rising burden of cancer. Traditional biopsy
methods, such as surgical excision biopsies, are often associated
with pain, longer recovery times, and higher risks of complications. In
contrast, minimally invasive biopsy techniques, including liquid biopsy,
fine-needle aspiration biopsy (FNAB), and image-guided core needle biopsy,
offer greater precision, reduced patient discomfort, and faster recovery,
making them the preferred choice among both patients and healthcare providers.
One of the key factors fueling this trend
is technological advancements that have enhanced the accuracy and
efficiency of minimally invasive biopsy techniques. Liquid biopsy, for
instance, is gaining widespread acceptance as it enables non-invasive
cancer detection through a simple blood draw, eliminating the need for surgical
intervention. With increasing R&D investments, next-generation
sequencing (NGS), circulating tumor DNA (ctDNA) analysis, and AI-driven
pathology solutions are further improving biopsy accuracy, making
early-stage cancer detection more effective.
Moreover, the demand for ambulatory and
outpatient diagnostic solutions is rising, particularly in urban
centers such as Delhi, Mumbai, Bengaluru, and Chennai, where patients
seek quick, safe, and convenient diagnostic options. Hospitals and
diagnostic centers are increasingly integrating robotic-assisted biopsy
systems and AI-based imaging technologies to improve diagnostic precision
and enhance patient outcomes. The private healthcare sector, which dominates
India's diagnostic landscape, is actively investing in state-of-the-art
minimally invasive biopsy solutions to meet the growing demand for
advanced cancer diagnostics.
Segmental Insights
Product
Insights
Based on Product, Tests emerged as
the dominating segment in the India Minimally Invasive Biopsy Techniques Market
in 2024, driven by rising demand for early cancer detection, technological
advancements, and increased accessibility of diagnostic solutions. The shift
towards non-invasive and highly accurate biopsy tests is accelerating due to
the growing burden of cancer in India, with one in nine people at risk of
developing cancer in their lifetime.
Among minimally invasive biopsy tests,
liquid biopsy has gained significant traction, offering a less painful, faster,
and highly precise alternative to traditional tissue biopsies. The increasing
adoption of circulating tumor DNA (ctDNA), exosome-based, and cell-free DNA
(cfDNA) tests is improving early cancer diagnosis, particularly for lung,
breast, and colorectal cancers, which are among the most prevalent in India.
Next-generation sequencing (NGS)-based tests are playing a
crucial role in personalized medicine, enabling oncologists to tailor treatment
plans based on genetic profiles.
The increasing penetration of private
diagnostic chains and government-backed screening programs is further fueling
the growth of this segment. With the expansion of healthcare infrastructure,
diagnostic facilities equipped with advanced molecular and genomic testing
technologies are becoming more widely available across metro cities as well as
tier-2 and tier-3 regions.
Application
Insights
Based on Application, Clinical emerged as the dominating segment in the India Minimally Invasive Biopsy
Techniques Market in 2024, driven by the increasing demand for early
cancer detection, disease monitoring, and routine diagnostic screenings.
The rising cancer prevalence in India, where one in nine individuals is
likely to develop cancer in their lifetime, along with a projected 12.8%
increase in cancer cases by 2025, underscores the urgent need for efficient and
accurate diagnostic solutions.
Minimally invasive biopsy techniques, such
as liquid biopsy, fine-needle aspiration biopsy (FNAB), and image-guided
core needle biopsy, are gaining widespread adoption in clinical settings due to
their non-invasive nature, reduced patient discomfort, and faster results.
The growing availability of advanced molecular and genetic testing in
private diagnostic centers and hospitals has further strengthened the dominance
of the clinical segment. Moreover, the integration of next-generation
sequencing (NGS) and AI-driven pathology solutions is enhancing diagnostic
accuracy, particularly for cancers such as lung, breast, colorectal, and
prostate cancer.
Download Free Sample Report
Regional Insights
Based on Region, North India emerged as the dominating region in the India Minimally Invasive Biopsy
Techniques Market in 2024, driven by a strong healthcare infrastructure, the
presence of top-tier hospitals and diagnostic centers, and rising cancer
prevalence. The region, which includes Delhi, Uttar Pradesh, Haryana, Punjab,
Rajasthan, and Uttarakhand, has seen a surge in the adoption of minimally
invasive biopsy techniques, fueled by increased awareness and government-backed
cancer screening initiatives.
Delhi, as the healthcare hub of India,
plays a crucial role in the region’s dominance, with AIIMS, Rajiv Gandhi Cancer
Institute, Max Super Speciality Hospital, and Fortis Memorial Research
Institute leading the adoption of advanced diagnostic technologies. Uttar Pradesh, the most populous state in India, has been
witnessing rapid expansion in healthcare services, with improved access to
minimally invasive diagnostic solutions, even in tier-2 and tier-3 cities such
as Lucknow, Kanpur, and Varanasi.
The high burden of cancer in North India
is a major factor driving the market. According to estimates, cancer incidence
is significantly rising in Delhi, Punjab, and Haryana, particularly for lung,
breast, and gastrointestinal cancers. This has led to a greater demand for
liquid biopsy, image-guided biopsy, and fine-needle aspiration biopsy (FNAB),
which are increasingly being integrated into routine diagnostics at private
hospitals and specialized oncology centers.
Recent Development
- In December 2024, PanGIA Biotech has
announced a landmark partnership to launch India’s first liquid biopsy assay
for prostate cancer, revolutionizing early detection and disease monitoring.
This innovative, non-invasive test analyzes circulating tumor markers in blood,
enabling accurate diagnosis and personalized treatment decisions. The
collaboration aims to enhance prostate cancer care, expand access, and improve
patient outcomes nationwide.
- In September 2024, Strand Life Sciences
has launched a liquid biopsy test, revolutionizing cancer diagnosis in India by
offering a non-invasive, highly accurate solution for detecting and monitoring
cancer. This advanced test analyzes circulating tumor DNA (ctDNA) from blood
samples, enabling early detection, treatment monitoring, and personalized
therapy decisions, significantly improving patient outcomes and expanding
access to precision oncology solutions.
- In March 2024, Amrita Hospital has
introduced a Minimally Invasive Salivary Gland Surgery Centre, enhancing
advanced treatment options for salivary gland disorders. This specialized
center utilizes endoscopic and image-guided techniques to perform precise,
scar-free procedures with minimal discomfort. The initiative aims to improve
patient outcomes, reduce recovery time, and advance minimally invasive surgical
practices in India’s healthcare sector.
- In February 2024, Fujifilm India has
launched the ALOKA ARIETTA 850 diagnostic ultrasound system, enhancing
high-precision imaging for advanced medical diagnostics. Equipped with
cutting-edge AI technology, superior image clarity, and real-time analysis,
this system supports accurate disease detection and minimally invasive
procedures. The innovation aims to improve healthcare efficiency and elevate
diagnostic capabilities across India.
Key Market Players
- Hoffmann-La
Roche AG
- Thermo
Fisher Scientific, Inc.
- PerkinElmer
Inc.
- QIAGEN
India Pvt. Ltd.
- Cardinal
Health International India Pvt Ltd
- B.
Braun SE
|
By Product
|
By Technique
|
By Circulating Biomarker
|
By Application
|
By End User
|
By Region
|
- Tests
- Kits & Consumables
- Instruments
|
- Liquid Biopsy
- Optical Biopsy
- Brush Biopsy
- Pigmented Lesion Assays
- Others
|
- Circulating Tumor Cells (CTCs)
- Cell Free DNA (cfDNA)
- Circulating Tumor DNA (ctDNA)
- Extracellular Vesicles
- Others
|
|
- Hospitals & Clinics
- Ambulatory Care Center
- Academic & Research Institutions
|
- East India
- West India
- North India
- South India
|
Report Scope
In this report, the India Minimally Invasive Biopsy
Techniques Market has been segmented into the following categories, in addition
to the industry trends which have also been detailed below:
- India Minimally Invasive
Biopsy Techniques Market, By Product:
o Tests
o Kits & Consumables
o Instruments
- India Minimally Invasive Biopsy
Techniques Market, By
Technique:
o Liquid Biopsy
o Optical Biopsy
o Brush Biopsy
o Pigmented Lesion Assays
o Others
- India Minimally Invasive
Biopsy Techniques Market, By Circulating
Biomarker:
o Circulating Tumor Cells (CTCs)
o Cell Free DNA (cfDNA)
o Circulating Tumor DNA (ctDNA)
o Extracellular Vesicles
o Others
- India Minimally Invasive
Biopsy Techniques Market, By Application:
o Clinical
o Therapeutic
- India Minimally Invasive
Biopsy Techniques Market, By End
User:
o Hospitals & Clinics
o Ambulatory Care Center
o Academic & Research Institutions
- India Minimally Invasive
Biopsy Techniques Market, By Region:
o East India
o West India
o North India
o South India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the India Minimally Invasive Biopsy Techniques Market.
Available Customizations:
India Minimally Invasive Biopsy Techniques Market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
India Minimally Invasive Biopsy Techniques Market
is an upcoming report to be released soon. If you wish an early delivery of
this report or want to confirm the date of release, please contact us at sales@techsciresearch.com